<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7438404\results\search\zoonosis\results.xml">
  <result pre="HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome coronavirus (SARS-CoV)," exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) and, most recently, SARS-CoV-2 (Graham et al.,"/>
  <result pre="therapies able to reduce the severity of clinical outcomes of" exact="coronavirus disease 2019" post="(COVID-19) and to reduce the spread of SARS-CoV-2. Here,"/>
  <result pre="a tendency, and the drug is already used to treat" exact="Influenza" post="viruses. Corsticosteroids (dexamethasone) NE Host factors (controlling immune response)"/>
  <result pre="it is reasonable to suggest that TACE inhibitors could hinder" exact="SARS-CoV infection." post="In this context, TAPI-2, a compound able to inhibit"/>
  <result pre="(Katz, 1977). Niclosamide presented antiviral activity on post-entry steps of" exact="SARS-CoV infection" post="in Vero cells, with an EC50 of 1â€&quot;3 Î¼M"/>
  <result pre="for instance, influenza A and B viruses, as well as" exact="Ebola" post="virus (EBOV) (Rossignol, 2014; Jasenosky et al., 2019), with"/>
  <result pre="an observational study with 81 patients with moderate to severe" exact="SARS-CoV-2 infection" post="(Lian et al., 2020) that demonstrated that Umifenovir neither"/>
  <result pre="have also been investigated due to their antiviral activity against" exact="Dengue" post="virus (DENV), Influenza A viruses, Chikungunya virus (CHIKV), and"/>
  <result pre="investigated due to their antiviral activity against Dengue virus (DENV)," exact="Influenza" post="A viruses, Chikungunya virus (CHIKV), and HIV (Tay et"/>
  <result pre="Al-Bari, 2017). Chloroquine was described as an entry inhibitor of" exact="SARS-CoV infection" post="in Vero cells and prevented cell-to-cell spread of the"/>
  <result pre="plasma/derivative is, in its turn, transfused into individuals with acute" exact="SARS-CoV-2 infection" post="(Garraud, 2017; Cao and Shi, 2020). Even though the"/>
  <result pre="further evaluation using in vivo systems of CoV infection, especially" exact="SARS-CoV-2 infection." post="The compounds are: NAAE, Glycyrrhizin, 2-acetamido-Î±- D-Glucopyranosylamine derivative, Tetrahydroquinoline"/>
  <result pre="2014). The development of refined and secure protocols to study" exact="SARS-CoV-2 infection" post="and its treatment options is required. Bearing in mind"/>
  <result pre="resistance to antiviral treatment, as observed for HIV, HCV, and" exact="Influenza" post="viruses (Laplante and St George, 2014; Li and Chung,"/>
  <result pre="(2014). Ribavirin and interferon therapy in patients infected with the" exact="Middle East respiratory syndrome" post="coronavirus: an observational study.Int. J. Infect. Dis.2042â€&quot;46. 10.1016/j.ijid.2013.12.00324406736 AnandK.ZiebuhrJ.WadhwaniP.MestersJ."/>
  <result pre="studies.Biosci. Trends1472â€&quot;73. 10.5582/BST.2020.0104732074550 GarraudO. (2017). Use of convalescent plasma in" exact="Ebola" post="virus infection.Transfus. Apher. Sci.5631â€&quot;34. 10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020)."/>
  <result pre="2019-nCoV and naming it SARS-CoV-2.Nat. Microbiol.5536â€&quot;544. 10.1038/s41564-020-0695-z32123347 GÃ¶tzV.MagarL.DornfeldD.GieseS.PohlmannA.HÃ¶perD.et al. (2016)." exact="Influenza" post="A viruses escape from MxA restriction at the expense"/>
  <result pre="bovine Coronaviruses.J. Virol.864631â€&quot;4643. 10.1128/JVI.06265-1122345457 GuanW.NiZ.HuY.LiangW.OuC.HeJ.et al. (2020). Clinical characteristics of" exact="Coronavirus disease 2019" post="in China.N. Engl. J. Med.3821708â€&quot;1720. 10.1056/NEJMoa200203232109013 HagaS.NagataN.OkamuraT.YamamotoN.SataT.YamamotoN.et al. (2010)."/>
  <result pre="with chronic hepatitis C treated with interferon-Î².Hepatology181319â€&quot;1325. 10.1002/hep.18401806068244255 LaiC.-C.ShihT.-P.KoW.-C.TangH.-J.HsuehP.-R. (2020)." exact="Severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic"/>
  <result pre="a less toxic derivative of chloroquine, is effective in inhibiting" exact="SARS-CoV-2 infection" post="in vitro.Cell Discov.61â€&quot;4. 10.1038/s41421-020-0156-031934347 LuG.WangQ.GaoG. F. (2015). Bat-to-human: spike"/>
  <result pre="Lond. Engl.3951033â€&quot;1034. 10.1016/S0140-6736(20)30628-0 MilletJ. K.SÃ©ronK.LabittR. N.DanneelsA.PalmerK. E.WhittakerG. R.et al. (2016)." exact="Middle East respiratory syndrome" post="coronavirus infection is inhibited by griffithsin.Antiviral Res.1331â€&quot;8. 10.1016/j.antiviral.2016.07.01127424494 MillsA."/>
  <result pre="(2016). Nitazoxanide, a new drug candidate for the treatment of" exact="Middle East respiratory syndrome" post="coronavirus.J. Infect. Public Health9227â€&quot;230. 10.1016/j.jiph.2016.04.00127095301 Ruiz-IrastorzaG.Ramos-CasalsM.Brito-ZeronP.KhamashtaM. A. (2010). Clinical"/>
  <result pre="infection in vitro and in vivo.Antiviral Res.99100â€&quot;107. 10.1016/j.antiviral.2013.04.01623648708 TakashitaE. (2020)." exact="Influenza" post="polymerase inhibitors: mechanisms of action and resistance.Cold Spring Harb."/>
  <result pre="al. (2016). Therapeutic efficacy of the small molecule GS-5734 against" exact="Ebola" post="virus in rhesus monkeys.Nature531381â€&quot;385. 10.1038/nature1718026934220 WeissS. R.Navas-MartinS. (2005). Coronavirus"/>
  <result pre="Biochem.821103â€&quot;1108. 10.1093/oxfordjournals.jbchem.a131782200604 ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.et al. (2020). Corticosteroid treatment of patients with" exact="coronavirus disease 2019" post="(COVID-19).Med. J. Aust.212416â€&quot;420. 10.5694/mja2.5057732266987 ZhangC.WuZ.LiJ.ZhaoH.WangG. (2020a). Cytokine release syndrome"/>
 </snippets>
</snippetsTree>
